Dual Inhibition of Mast Cells and Thymic Stromal Lymphopoietin Using a Novel Bispecific Antibody, <scp>CDX</scp> ‐622
CDX-622 is a potent inhibitor of MCs through the neutralization of SCF and effectively blocks Type 2 inflammatory responses driven by TSLP. Dual inhibition of these cytokines may lead to improved clinical outcomes in certain inflammatory disorders.
Authors
- Kelly M. McManus
- Tibor Keler (ORCID: https://orcid.org/0000-0003-1757-4230)
- Russell A. Hammond
- Noe Rico Montanari (ORCID: https://orcid.org/0000-0002-2211-8881)
- Laura Vitale (ORCID: https://orcid.org/0000-0003-2831-1794)
- Thomas J. O’Neill (ORCID: https://orcid.org/0000-0003-2253-3118)
- Deena M. Maurer
- James M. Boyer
- Colleen Patterson
- Laura Mills‐Chen
- Lawrence J. Thomas (ORCID: https://orcid.org/0000-0002-5343-406X)
- Diego Alexander Garzón Alvarado (ORCID: https://orcid.org/0009-0003-2486-9560)
- Andrea Crocker
- Linda Malenchek
- J. Goldstein (ORCID: https://orcid.org/0000-0003-1591-6014)
- Miles Murphy
- Virginia Saley
- Nicole M. Antczak
Institutions
- Celldex Therapeutics (United States) (US)
Publication Details
- Journal
- Allergy
- Published
- 2025-02-20
- DOI
- https://doi.org/10.1111/all.16509
- Citations
- 4
- Primary Topic
- Allergic Rhinitis and Sensitization
- Type
- article
- Field-Weighted Citation Impact
- 6.49
Funders
- Celldex Therapeutics